AndhraNews.net
Home » Business News » 2015 » November » November 2, 2015

StockNewsNow.com Publishes Q3 2015 Review SNNLive Video Interview With Immune Pharmaceuticals, Inc.


November 2, 2015 - LOS ANGELES, CA

LOS ANGELES, CA--(Marketwired - November 02, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), applies a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted, monoclonal antibody therapeutics, according to the company's website (see here: http://immunepharmaceuticals.com/). The video interview was recorded on Thursday, October 15th, 2015 at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Q3 2015 Review with Immune Pharmaceuticals, Inc. - Update on Clinical and Corporate Developments

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Immune Pharmaceuticals

Immune applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology; topical nano-formulated Cyclosporine A for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nano-conjugates, for the targeted delivery of chemotherapeutics. Immune's Pain pipeline including AmiKet™ are in a partnering process for further development and commercialization. For more information and company description, visit Immune's website at www.immunepharmaceuticals.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=N8NSWTfS9Tg

StockNewsNow.com
Email contact

MarketWire

Comment on this story

Share